Common CPT Codes in Oncology Billing

Oncology coding is one of the most detail-driven areas in medical billing. Cancer treatment involves multiple disciplines, medical oncology, radiation oncology, surgical oncology, pathology, and more. Each step of the patient journey requires precise coding to capture services for reimbursement, compliance, and quality reporting.

In oncology, coding mistakes rarely stay isolated. A missed infusion hour, unsupported molecular test, incorrect sequencing designation, or incomplete radiation modifier can quietly impact reimbursement across hundreds of claims before the issue is identified.

In 2026, oncology billing teams are also facing tighter payer scrutiny around infusion documentation, drug wastage reporting, medical necessity validation, and molecular pathology reimbursement. Commercial payers are increasing prepayment review activity for high-cost biologics, immunotherapy drugs, genomic testing, and CAR T-cell therapies, while CMS continues expanding audit oversight across oncology infusion and radiation services.

At the same time, oncology care continues growing rapidly. According to the American Cancer Society, there are an estimated 2 million new cancer cases annually in the United States, while national cancer care spending is projected to exceed $240 billion by 2030. With such a large financial footprint, accurate coding is critical to keeping oncology practices financially healthy and ensuring patients continue receiving uninterrupted care.

CPT codes are the language payers use to understand what services were provided. In oncology, these codes cover everything from initial consultations and chemotherapy administration to radiation treatment planning and new therapies like CAR T-cell. 

The following guide walks through the most common CPT codes in oncology billing, offering practical explanations to help coders and billers capture services accurately.

Why CPT Codes Matter in Oncology

Every oncology service needs to be linked with the correct CPT code. Incomplete or inaccurate reporting can result in delayed reimbursements, underpayments, or unnecessary rework. But more importantly, coding accuracy also supports:

• Patient trust – ensuring patients are billed correctly for complex care.
• Revenue cycle efficiency – preventing denials and reducing administrative backlogs.
• Compliance – aligning with CMS and payer-specific rules for oncology services.
• Data-driven care – coding data feeds into cancer registries, treatment audits, and outcome studies.

Oncology coding isn’t about memorizing numbers; it’s about understanding which code best represents the service delivered in a specific clinical context.

Evaluation and Management (E/M) Codes in Oncology

Oncology often starts with evaluation, discussing a diagnosis, staging the disease, and planning treatment. CPT codes for Evaluation and Management (E/M) visits are some of the most frequently reported.

99202–99205: New patient office visits

Used when oncology physicians evaluate a patient for an initial cancer diagnosis, treatment planning, or specialist consultation. Code selection depends on medical decision-making complexity or total time spent reviewing records, discussing treatment risks, coordinating care, and developing oncology management plans 

99211–99215: Established patient visits

Reported for ongoing oncology follow-up visits involving chemotherapy management, symptom monitoring, treatment adjustments, toxicity review, survivorship care, or coordination with multiple specialists. Oncology encounters often support higher-level E/M coding because of extensive medical decision-making complexity. 

Because oncology involves high-complexity decision-making, coders should pay attention to time spent and medical decision-making (MDM) level. For example, oncology physicians frequently spend extended time reviewing lab results, imaging studies, and coordinating multi-specialty care. Proper documentation of complexity ensures accurate coding at higher levels, which directly affects reimbursement.

Chemotherapy Administration Codes (96400–96549)

Chemotherapy coding is one of the most essential skills in oncology billing. These codes capture how chemotherapy drugs are administered, whether by intravenous infusion, push, or other routes.

96413 – Chemotherapy, intravenous infusion, up to 1 hour, initial

Used for the first hour of intravenous chemotherapy infusion administration in outpatient oncology settings. Accurate billing requires infusion start and stop times, drug sequencing documentation, nursing administration records, and confirmation that the infused substance qualifies as chemotherapy under payer guidelines. 

96415 – Each additional hour (after 96413)

Add-on code used for prolonged chemotherapy infusions extending beyond the initial hour billed under 96413. Documentation must clearly support continuous infusion time exceeding the first hour threshold and ongoing monitoring throughout the treatment encounter. 

96409 – IV push, single or initial substance

Reported when antineoplastic chemotherapy agents are administered by IV push rather than prolonged infusion. Coders should confirm administration method, sequencing, and whether the drug qualifies under chemotherapy administration guidelines instead of therapeutic infusion rules. 

96411- Each additional sequential IV push

Add-on code used when additional chemotherapy agents are administered by IV push following the initial push service. Accurate reporting depends on correct sequencing documentation and clear distinction between chemotherapy agents and supportive medications. 

Why it matters: Chemotherapy codes are time-based. Coders must know when an infusion starts, how long it runs, and whether additional drugs are administered sequentially or concurrently. Missing these details leads to lost revenue.

Supporting services like hydration or antiemetic administration have their own CPT codes (e.g., 96360–96361), but they cannot be billed as chemotherapy unless documented as such.These services cannot automatically be billed as chemotherapy administration unless documentation clearly supports chemotherapy classification 

Radiation Oncology CPT Codes

Radiation therapy uses its own category of CPT codes because it includes planning, dosimetry calculation, simulation, treatment delivery, and ongoing management over multiple sessions. Radiation oncology coding can be complex since treatment often occurs over multiple sessions.

Common CPT codes include:

77261–77263: Radiation therapy planning (simple to complex)

Used for simple, intermediate, and complex radiation treatment planning services. Documentation must support physician evaluation of treatment fields, tumor complexity, imaging review, dosing strategy, and treatment approach development. 

77300 – Basic radiation dosimetry calculation

Reported for radiation dose calculations supporting treatment planning and delivery. The medical record should demonstrate physician or physicist involvement in determining radiation dosing parameters and treatment calculations. 

77427 – Radiation treatment management

Used for physician management of radiation therapy over a defined treatment cycle. Documentation should support active treatment management, patient evaluation, treatment review, and supervision during the specified number of fractions. 

77790 – Supervision of radiation therapy, complex cases

Reported for physician supervision associated with complex radiation treatment delivery. Accurate reporting depends on clear supervision documentation and alignment between treatment planning and execution records. 

One key difference in radiation oncology is global vs technical vs professional components. Coders should apply modifiers based on whether the physician only supervised or also performed the service. 

Modifiers such as -26 and -TC remain especially important in radiation oncology billing when professional interpretation and technical delivery components are split between providers or facilities. 

Key Changes in Radiation Oncology CPT Codes   

Radiation oncology billing in 2026 saw a major restructuring of CPT codes. The focus shifted from technology‑specific codes to complexity‑based tiers, with image guidance bundled into delivery codes. This streamlining aims to reduce redundancy, improve payer consistency, and align reimbursement with treatment intensity rather than equipment type.

Code	Description	Change
77402	Radiation treatment delivery, Level 1 (e.g., 2D photons, electron fields)	Consolidated entry‑level delivery code
77407	Radiation treatment delivery, Level 2 (single isocenter, 3D or IMRT photons)	Mid‑complexity delivery code
77412	Radiation treatment delivery, Level 3 (multiple isocenters, motion management, total skin electrons, mixed fields)	High‑complexity delivery code
77387	Image guidance, professional component only	Technical component bundled into delivery codes
Deleted Codes	77385, 77386 (IMRT delivery), 77014 (CT guidance), G6001–G6017	Removed; replaced by consolidated delivery codes

Practices must adapt by strengthening documentation workflows, training coders on the new hierarchy, and ensuring audit‑ready claims. 

Infusion and Supportive Therapy Codes

Not every oncology infusion is chemotherapy. Many patients receive supportive therapies, such as hydration, antiemetics, or growth factor injections. These use non-chemo infusion codes:

96365 – Initial IV infusion, up to 1 hour for therapeutic, prophylactic, or diagnostic drug administration

Used for non-chemotherapy infusions such as antibiotics, electrolyte replacement, biologic supportive medications, or hydration therapies. Documentation should identify the infused substance, administration route, and infusion duration. 

96366 – Each additional hour of therapeutic infusion

Add-on code used when supportive or therapeutic infusions continue beyond the initial hour. Accurate reporting requires clearly documented infusion duration exceeding the primary service threshold. 

96372 – Therapeutic, prophylactic, or diagnostic injection

Reported for subcutaneous or intramuscular injections commonly used in oncology supportive care, including growth factor injections, antiemetics, or hormonal therapies.
These codes ensure that supportive care, often essential for quality of life during cancer treatment, is properly documented and reimbursed. Coders should be careful not to confuse them with chemotherapy codes.

Pathology and Laboratory Codes in Oncology

Oncology depends heavily on pathology biomarker testing, and molecular diagnostics to guide treatment decisions. As precision medicine expands, pathology coding has become increasingly important in oncology reimbursement workflows. 

Common Pathology and Molecular Oncology CPT Codes 

88305 – Level IV surgical pathology (commonly used for biopsies)

Commonly used for biopsy specimen evaluation and tissue pathology interpretation. Documentation must support specimen analysis complexity and physician pathology review associated with cancer diagnosis. 

88342 – Immunohistochemistry (IHC) per specimen

Used when tumor tissue undergoes immunohistochemical staining to identify biomarkers, receptor status, or tumor classification markers that influence treatment planning. 

88360 – Morphometric analysis, quantitative immunohistochemistry

Reported for advanced biomarker analysis involving quantitative measurement and interpretation supporting targeted oncology therapies or precision medicine treatment selection. 

81445 – Solid Organ Tumor Genomic Sequencing Panel

One of the most commonly reviewed molecular oncology codes in 2026. This code is used for targeted genomic sequencing panels evaluating tumor mutations associated with solid organ cancers. Payers increasingly require:

• Prior authorization
• Biomarker-specific medical necessity
• NCCN guideline support
• Documentation of treatment impact
• FDA-approved therapy linkage

Claims lacking treatment relevance documentation are frequently denied

81455 – Comprehensive Genomic Sequencing Panel

One of the highest-scrutiny molecular pathology CPT codes in oncology billing today.

81455 is used for expanded genomic sequencing panels involving large-scale tumor mutation analysis and precision medicine treatment selection.

In 2026, commercial payers are aggressively reviewing:

• Panel size appropriateness
• Medical necessity
• Previous treatment failure
• Targeted therapy eligibility
• Supporting oncology guidelines
• Duplicate testing frequency

 Because these tests are expensive, unsupported genomic sequencing claims are becoming a major oncology audit target.

In 2026, molecular oncology billing continues seeing increased payer scrutiny. Commercial payers and Medicare contractors are reviewing genomic sequencing claims, biomarker testing utilization, and next-generation sequencing reimbursement more aggressively because of rapidly rising oncology testing costs. 

These codes reflect the work of pathologists in identifying tumor type, staging, and molecular markers that guide targeted therapy. As oncology shifts toward personalized medicine, molecular testing codes are increasingly important.

New and Emerging Codes: CAR T-Cell Therapy

Innovations in oncology bring new codes. One example is CAR T-cell therapy, a type of immunotherapy where a patient’s T-cells are modified and reintroduced to fight cancer.

38225 – Bone marrow biopsy and aspiration

Used during hematology and oncology treatment evaluation, often supporting cell-based therapy preparation or disease assessment before advanced oncology treatment. 

38230–38232 – Cell harvesting and preparation

Reported for collection, preparation, and processing of cellular therapy products associated with advanced oncology treatment pathways including CAR T-cell therapy. 

38999 – Unlisted hematology procedure (used in certain CAR T contexts, until newer codes are added)

Used in select oncology scenarios where emerging therapies or advanced procedures do not yet have established CPT codes. Supporting documentation must clearly describe the service performed and medical necessity rationale. 

CAR T-cell therapy is expensive, costing upwards of $373,000 per patient (NCI CAR T-cell therapy data). Coders need to be up to date on how payers are reimbursing these services since new codes continue to evolve.

Common Oncology Coding Challenges

Even with clear guidelines, oncology billing presents challenges:

• Drug vs administration coding – Both the drug (HCPCS J-codes) and the administration (CPT codes) must be captured.
• Concurrent vs sequential infusions – Misclassifying can change reimbursement significantly.
• Modifiers in radiation therapy – Incorrect use of -26 or -TC leads to payment delays.
• Emerging therapies – Coders must keep up with new oncology codes updated annually by CPT and CMS.

As payer audit systems become more automated, oncology claims with inconsistent infusion records, unsupported molecular testing, or incomplete administration details are being flagged faster. 

Oncology CPT and ICD-10 Quick Reference

One of the most common oncology billing mistakes involves incorrect ICD-10 diagnosis linkage. Even when the CPT code is correct, claims may still deny if the diagnosis does not properly support medical necessity.

Below are common oncology CPT and ICD-10 coding combinations frequently used in oncology billing.

CPT Code	Service Description	Common ICD-10 Pairing
96413	Initial chemotherapy infusion	C50.9 Malignant neoplasm of breast
96415	Additional hour chemotherapy infusion	C34.90 Malignant neoplasm of lung
77427	Radiation treatment management	C61 Malignant neoplasm of prostate
77301	IMRT treatment planning	C71.9 Malignant neoplasm of brain
81445	Tumor genomic sequencing panel	C18.9 Malignant neoplasm of colon
81455	Comprehensive genomic sequencing	C25.9 Malignant neoplasm of pancreas
96365	Therapeutic infusion	C56.9 Malignant neoplasm of ovary
88342	Immunohistochemistry	C67.9 Malignant neoplasm of bladder

Coders should always verify payer-specific medical necessity requirements because diagnosis support rules can vary significantly across commercial plans and Medicare contractors. 

Best Practices for Oncology Coding

To strengthen oncology billing accuracy, consider these coding best practices:

• Stay current – CPT codes are updated annually; oncology has frequent changes.
• Use checklists – For chemotherapy, always document start time, stop time, and drug details.
• Pair ICD-10 and CPT correctly – Diagnoses like malignant neoplasm of breast (C50.9) must be paired with chemo administration codes.
• Leverage technology – Use coding software and scrubbers to catch mismatches before submission.
• Educate providers – Proper documentation starts with physicians and nursing staff noting time, drug, and route accurately.

By staying current, documenting thoroughly, and aligning ICD‑10 with CPT codes, oncology practices can reduce denials, safeguard reimbursement, and maintain compliance integrity. 

Oncology Billing Built on Compliance and Care 

Keeping oncology billing compliant and financially stable takes more than knowing the right CPT codes. Practices also need strong documentation workflows, accurate infusion reporting, proactive denial prevention, and a revenue cycle strategy that can keep up with evolving payer scrutiny.

That’s where specialized oncology billing support becomes critical.

AnnexMed helps oncology practices improve coding accuracy, strengthen claim quality, reduce denials, and streamline reimbursement workflows across chemotherapy administration, radiation oncology, infusion services, pathology billing, and molecular diagnostics. 

From modifier validation and infusion charge capture to AR follow-up and payer compliance management, our oncology RCM teams help practices stay audit-ready while protecting long-term revenue performance.

FAQs

1. What is the JW modifier in oncology billing?

The JW modifier is used when a single‑use vial or package of a drug is not fully administered and the remainder is discarded. It allows practices to bill for the amount given while documenting wastage for compliance and reimbursement.

2. Can 96413 and 96415 be billed on the same day?

Yes. 96413 covers the initial hour of chemotherapy infusion, and 96415 is used for each additional hour. They are billed together when infusion extends beyond the first hour, with documentation of start/stop times required.

3. What ICD‑10 codes support chemotherapy administration?

Common ICD‑10 codes include Z51.11 (encounter for antineoplastic chemotherapy) and cancer‑specific codes such as C50.9 (malignant neoplasm of breast, unspecified). The ICD‑10 must match the clinical diagnosis driving the chemotherapy.

4. What is concurrent vs sequential infusion billing?\

Concurrent infusion → Two drugs infused at the same time through separate lines; billed with concurrent infusion codes.

Sequential infusion → One drug infused after another in the same line; billed with sequential infusion codes. 

Accurate documentation of timing and sequence is critical to avoid denials.

5. Does radiation therapy require prior authorization in 2026?

Yes. Prior authorization is required for the new consolidated delivery codes (77402, 77407, 77412) and the professional component of image guidance (77387‑26). Older codes like 77385, 77386, and related G‑codes were deleted, so workflows must be updated to reflect the new requirements.

6. Are HCPCS J‑codes required alongside CPT codes for chemotherapy?

Yes. CPT codes describe the administration service (e.g., 96413 for infusion), while HCPCS J‑codes identify the specific drug and dosage given. Both must be reported together, with exact units and modifiers (JW/JZ for wastage) to ensure compliance and avoid denials.